FOLH1 and neoplasm: Because of its commercial availability and putatively higher fluorescence intensity and photostability [23], we switched to the DyLight800 fluorophore and altered the structure of the linker between the fluorophore and the PSMA-targeting moiety in a series of compounds to optimize performance, i.e., tumor visualization in vivo at 24 h post-injection.